[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaginal-dryness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaginal-dryness":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,87,118,145,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100649631","retrospective-cohort-study-of-symptoms-and-quality-of-life-in-women-with-genitourinary-syndrome-of-menopause-100649631",false,"NCT07737782","Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.","Retrospective Observational Study in a Cohort of Postmenopausal Women With Genitourinary Syndrome of Menopause (GSM): Characterization of Symptoms and Impact on Quality of Life.","Inclusion Criteria:\n\nPatients included in this retrospective data evaluation must have met all of the following criteria:\n\n* Postmenopausal women (defined as at least 12 consecutive months of amenorrhea)\n* Present at least one symptom of GSM documented in the medical record\n* Evidence in the medical record that the patient had perceived the GSM symptom(s) as having an impact on her quality of life.\n* Documentation in the medical record that the patient had initiated treatment with XCM INTIM, together with follow-up clinical data including an assessment performed at least 8 weeks after treatment initiation.\n* Patients that had attended at the Department of Obstetrics and Gynecology of Hospital Universitario La Luz between January 2022 and April 2026, regardless of whether they had participated in another study during this period.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if any of the following conditions were present:\n\n* Use of topical vulvovaginal hormonal products within 4 weeks prior to initiation of XCM INTIM treatment.\n* Use of systemic estrogen therapy within 8 weeks prior to initiation of XCM INTIM treatment.\n* Presence of relevant gynecological and\u002For urinary conditions that could have interfered with the assessment of symptoms attributed to GSM, including but not limited to active vulvovaginal and\u002For urinary tract infections, significant vulvar lesions, active gynecological malignancies, severe stress urinary incontinence (Sandvik score ≥ 8), pelvic organ prolapse stage III or higher (POP-Q), or any other condition considered by the investigator to be a significant confounding factor.\n* Previous radiotherapy involving the pelvic and\u002For genital region.\n* Previous laser and\u002For radiofrequency treatment in the pelvic region.\n* Medical records containing insufficient information for analysis of the primary study variables.","FEMALE","40 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to retrospectively identify the most prevalent symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women and to evaluate their impact on quality of life. Moreover, based on data collected from medical records and\u002For patient-reported questionnaires, if available data enable it, it will be assessed whether treatment with the topical vulvovaginal gel XCM INTIM for a minimum of 8 weeks results in changes in symptom severity and in the impact of these symptoms across different quality-of-life domains.",[25,26,27,28,29,30,31,32,33,34],"Vulvar Atrophy","Vulvovaginal Signs and Symptoms","Genitourinary Syndrome of Menopause (GSM)","Quality of Life","Menopause Related Conditions","Dyspareunia","Urinary Incontinence, Urgency-frequency","Sexual Function","Women´s Health","Vaginal Dryness",[36,26,37,28,38,33,39],"Genitourinary Syndrome of Menopause","Patient Reported Outcome Measures","Day-to-Day Impact of Vaginal Ageing","Real World Data","NOT_YET_RECRUITING","2026-07-28",{"date":43,"type":44},"2026-07-30","ACTUAL",{"date":46,"type":21},"2026-07",{"date":48,"type":21},"2026-09",{"name":50,"class":51},"Mucosa Innovations, S.L.","INDUSTRY",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100645580","f-gyn-for-vaginal-dryness-and-vulvovaginal-atrophy-100645580","NCT07701863","F-GYN for Vaginal Dryness and Vulvovaginal Atrophy","Evaluation of the Efficacy and Safety of Intravaginal Injections of the F-GYN Medical Device in Relieving Symptoms of Vaginal Dryness and Improving Signs of Vaginal and Vestibular Atrophy","F-GYN","Inclusion Criteria:\n\n* Female participants.\n* Age over 18 years.\n* Decreased moisture of the vaginal and\u002For vestibular mucosa confirmed by the investigator during gynecological examination, defined as a moisture\u002Ffluid volume domain score of 3 or less on a 5-point scale.\n* Participant-reported vaginal dryness and\u002For pain during sexual intercourse with a score of at least 5 on an 11-point numeric rating scale at the baseline visit.\n* Willingness not to use intravaginal or systemic hormonal therapies for the treatment of vaginal dryness or vaginal atrophy during the study. Stable hormonal contraception without planned changes during the study is allowed.\n* Willingness to report all medications, intravaginal products, vaginal gels, creams, suppositories, lubricants, and other products used to relieve symptoms of vaginal dryness during the study.\n* Ability and willingness to provide voluntary written informed consent before any study-related procedures.\n* For participants of childbearing potential: negative urine pregnancy test at the baseline visit and, for participants assigned to the control arm, also before F-GYN injection; willingness to use a method of contraception accepted by the investigator throughout the study.\n\nExclusion Criteria:\n\n* Menstruation or genital tract bleeding of unknown cause on the day of the screening\u002Fbaseline visit.\n* Pregnancy, breastfeeding, or planned pregnancy during the study.\n* Presence of varices, open wounds, ulcers, active infections, or other clinically significant damage of the vaginal or vestibular mucosa at the planned injection sites.\n* Tendency to develop hypertrophic scars or keloids.\n* Active vaginal or vulvar infection, including viral, bacterial, or fungal infection.\n* Active urinary tract infection.\n* Other genital tract conditions that, in the investigator's opinion, could affect assessment of study outcomes.\n* Severe disease or other medical condition that, in the investigator's opinion, could affect assessment of study outcomes or participant safety.\n* Local treatment in the study area within 4 weeks before the baseline visit that could significantly affect study outcomes, including intravaginal hormonal products such as suppositories, creams, or vaginal tablets.\n* Use of intravaginal products containing hyaluronic acid or other substances with a potentially long-lasting effect on vaginal mucosal atrophy within 4 weeks before the baseline visit.\n* Systemic hormonal therapy or estrogen receptor modulation, such as selective estrogen receptor modulators, that could affect the vaginal mucosa within 8 weeks before the baseline visit.\n* Anti-estrogen therapy, including tamoxifen or aromatase inhibitors, for hormone-dependent breast cancer within 12 months before the baseline visit.\n* Injection procedures at the planned injection sites, such as hyaluronic acid, platelet-rich plasma, or other injectable therapies, within 6 months before the start of the study.\n* Device-based procedures with potential effects on vaginal mucosal atrophy at the planned treatment area, such as CO₂ laser, radiofrequency, or similar procedures, within 6 months before the start of the study.\n* Use of anticoagulant or antiplatelet medication.\n* Clinically significant coagulation disorder.\n* Known hypersensitivity to any component of the investigational device, local anesthetic, or antiseptic solution.\n* Current participation or planned participation in another clinical study during participation in the F-GYN study.","18 Years",{"count":63,"type":21},130,"INTERVENTIONAL",[66],"NA","This clinical study will evaluate the efficacy and safety of F-GYN, a sterile injectable medical device containing non-crosslinked hyaluronic acid, in adult women with moderate to severe vaginal dryness and symptoms related to vaginal and vestibular atrophy.\n\nVaginal dryness and atrophic changes may cause discomfort, itching, burning, pain during sexual intercourse, reduced lubrication, and lower quality of life. Standard non-hormonal products, such as lubricants and moisturizers, may not provide sufficient relief for all women, and hormonal therapies may be unsuitable or unacceptable for some patients.\n\nParticipants will be randomly assigned to one of two groups. Participants in the study group will receive one F-GYN injection at the baseline visit. Participants in the control group will continue standard non-hormonal symptomatic care for 4 weeks and will then receive one F-GYN injection after all planned 4-week assessments have been completed. This allows F-GYN to be compared with standard non-hormonal care during the initial 4-week comparison period.\n\nThe injection will be administered by a qualified gynecologist into the vaginal and vestibular tissue. Local anesthesia may be used according to the standard practice of the study site.\n\nThe main purpose of the study is to determine whether F-GYN improves vaginal health, assessed by the Vaginal Health Index, after 4 weeks compared with standard non-hormonal symptomatic care without injection. The study will also assess vaginal dryness, itching, burning, pain during sexual intercourse, quality of life, sexual comfort, treatment satisfaction, global improvement, and safety. Participants will attend study visits and will also complete telephone follow-up questionnaires up to 6 months after the injection.",[69,70,71,30,72,34],"Atrophic Vaginitis","Atrophic Vulvovaginitis","Vaginal Atrophy","Vulvo Vaginal Atrophy",[74,75,34,76,77,30,78],"Non-Crosslinked Hyaluronic Acid","Intravaginal Injection","Vulvovaginal Atrophy","Vestibular Atrophy","Vaginal Mucosal Hydration","2026-07-08",{"date":81,"type":44},"2026-07-14",{"date":46,"type":21},{"date":84,"type":21},"2027-08",{"name":86,"class":51},"Biovico Sp. z o.o.",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":64,"phases":98,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100641575","veda-study-dhea-vs-estradiol-100641575","NCT07574216","VEDA Study (DHEA vs Estradiol)","The Use of Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women","Inclusion Criteria:\n\n* Peri- or post-menopausal status\n* Presence of any genitourinary or vaginal symptom (e.g., dryness, itching, discomfort, dyspareunia)\n* Willingness and ability to use vaginal therapy\n* Ability to provide informed consent\n* English speaker\n* Ages 40-90\n\nExclusion Criteria:\n\n* Use of systemic hormone therapy within the last 6 months\n* Gynecologic malignancy\n* Known allergy to study medications\n* Active vaginal infection at enrollment\n* Prior pelvic radiation",true,"90 Years",{"count":97,"type":21},324,[66],"This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.",[101,102,32,103,34,104],"Post-menopause","Pre-menopause","Menopause","Painful Intercourse",[106,107],"DHEA","vaginal estrogen","2026-06-15",{"date":110,"type":44},"2026-06-17",{"date":112,"type":21},"2026-06-01",{"date":114,"type":21},"2031-12-31",{"name":116,"class":117},"University of Arizona","OTHER",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":94,"sex":16,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":64,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":52},"100622640","exploration-of-the-effect-of-a-wheat-polar-lipid-complex-on-vaginal-dryness-in-healthy-postmenopausal-women-100622640","NCT07386249","Exploration of the Effect of a Wheat Polar Lipid Complex on Vaginal Dryness in Healthy Postmenopausal Women","Inclusion Criteria:\n\n* Healthy woman, aged of 45 to 65 years (inclusive)\n* In postmenopause, defined according to the STRAW criteria as the absence of menstrual periods for at least 12 consecutive months\n* Reporting a vaginal dryness intensity score ≥ 4 on a 0-10 Visual Analogue Scale (VAS), and a score ≥ 16 on the Menopause Rating Scale (MRS)\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Stated willingness to maintain their usual life habits (diet, physical activity, alcohol consumption…)\n* Speaking French.\n\nExclusion Criteria:\n\n* Use of systemic hormonal therapy within the past 3 months\n* Use of dietary supplements, herbal products, or over-the-counter remedies intended to alleviate menopausal symptoms within 4 weeks prior to the screening visit (wash-out period ≥ 1 month required)\n* Use of vaginal hormonal formulations within 4 weeks prior to screening\n* History of hormone-dependent cancers\n* History of hysterectomy or bilateral oophorectomy\n* Current alcohol dependence or excessive alcohol consumption exceeding an average of 14 standard drinks per week\n* Current use of illicit drugs or recent history of drug dependence\n* Current or previously diagnosed eating disorders considered likely to impact participant safety or study outcomes\n* Presence of severe or uncontrolled chronic medical conditions, or any acute medical condition judged by the investigator to potentially interfere with the MRS assessment or participant safety\n* Subject participating in another intervention trial","45 Years","65 Years",{"count":127,"type":21},110,[66],"This study aims to explore the positive effect of a dietary supplement composed of wheat polar lipids on vaginal dryness in healthy postmenopausal women",[34,131],"Menopause Symptoms",[103,133,134],"Wheat polar lipids","Vaginal dryness","RECRUITING","2026-04-22",{"date":138,"type":44},"2026-04-23",{"date":140,"type":44},"2026-02-02",{"date":142,"type":21},"2026-11",{"name":144,"class":51},"Seppic",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":64,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":52},"100590048","changes-in-the-impact-of-genitourinary-syndrome-of-menopause-with-a-novel-nonhormonal-vulvovaginal-gel-assessed-by-proms-100590048","NCT06962345","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial. Part of STOP GSM PROJECT.","STOPGSMP","Inclusion Criteria:\n\n* Patient has to have at least one symptom of GSM or suffer from symptoms related to vulvovaginal atrophy (as evidenced by gynecological examination with a Vaginal Health Index ≤15).\n* Patient must be postmenopausal with at least 1 year without a menstrual period.\n* Patient must consider that her quality of life is affected by GSM symptoms\n* Patient not followed due to any gynecological disease.\n* All participants must be able to understand and to fill in the self-reported questionnaires.\n\nExclusion Criteria:\n\n* Patients that do not want to fill the questionnaire, especially the questions that address sexual functioning.\n* Participants that use any oral products containing hormones or estrogen receptor modulators for the past 8 weeks, nor vaginal topical hormone products within 4 weeks, neither prescription nor non-prescription therapies for GSM, including topical vaginal non-hormonal lubricants or moisturizers for the last week.\n* Patients with history of vulvar, vaginal and\u002For cervical malignancy.\n* Patients having received radiotherapy treatment in the pelvic and\u002For genital region.\n* Patients with any type of disease that causes alteration of collagenogenesis.\n* Patients that use cytotoxic drugs leading to mucositis and alterations of tissue regeneration in the last 6 months.\n* Patients having received laser and\u002For radiofrequency treatment for handling genital atrophy or other pelvic floor dysfunctions.\n* Patients with active urinary and\u002For genital tract infection.\n* Patients with history of malignant neoplasm of the urinary system.\n* Patients with severe stress urinary incontinence (Sandvik test score equal to or greater than 8).\n* Patients with diagnosis of pelvic organ prolapse grade III or higher according to the POP-Q classification.\n* Patients with medical or surgery history that, at the investigator's discretion, does not allow participation in the study.\n* Patients with any other condition that, at the investigator's discretion, implies that the patient is unable to understand the implication of participating in the study and\u002For following the established procedures.","70 Years",{"count":155,"type":21},80,[66],"The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.",[25,26,36,28,29,30,31,32,33,34],[36,26,37,28,38,33],"2026-03-25",{"date":162,"type":44},"2026-03-30",{"date":164,"type":44},"2024-01-08",{"date":166,"type":21},"2026-12",{"name":50,"class":51},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":64,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":52},"100585285","efficacy-and-safety-of-vaginal-radiofrequency-for-vulvovaginal-atrophy-in-breast-cancer-patients-100585285","NCT06900374","Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients","RF-Vaginale : Randomised Phase III Trial Evaluating the Efficacy and Safety of Vaginal Radiofrequency in the Management of Vulvovaginal Atrophy and Dryness in Patients Treated for Breast Cancer","RF-Vaginale","INCLUSION CRITERIA :\n\n* Patient over 40 years\n* Presenting disabling vaginal dryness symptoms despite well-administered local moisturizing treatment, attested by a vaginal dryness score ≥3\n* Patient undergoing adjuvant treatment for breast cancer\n* Patient treated with aromatase inhibitors +\u002F- LHRH agonist for at least 3 months with a planned remaining duration of at least 12 months\n* Patient affiliated to a social security organization\n* Patient having signed the informed consent for the present study\n\nEXCLUSION CRITERIA:\n\n* Contraindications related to the radiofrequency technique:\n\n  * Ongoing urinary tract infection\n  * Pacemaker\n  * IUD intrauterine device\n  * Pregnancy\n* Mucocutaneous disease with vulvovaginal localization: infection, sore, scleratrophic lichen, psoriasis, eczema, etc.\n* Neurodegenerative disease with perineal involvement\n* Current or recent treatment (within the last 12 months) with other physical methods: vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection or lipo-modeling.\n* Pregnant or breast-feeding women\n* Patients under guardianship or trusteeship.",{"count":177,"type":21},75,[66],"This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer.\n\nPatients will be randomly assigned to one of two parallel treatment groups until the six-month assessment:\n\nThe first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators.\n\nThe second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.",[34,181,76],"Breast Cancer",[134,183,184,185],"vaginal atrophy","vaginal radiofrequency","breast cancer","2026-03-16",{"date":188,"type":44},"2026-03-18",{"date":190,"type":44},"2025-06-12",{"date":192,"type":21},"2028-06",{"name":194,"class":117},"Centre Oscar Lambret"]